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Abstract
Objectives To determine the prevalence of serous retinal
detachments (SRD) using optical coherence tomography
(OCT) in a large database of patients with uveitis from a
tertiary referral setting, to describe clinical features of
patients with SRD, and to ascertain retinal architectural
features found in association with SRD.
Main outcome measures Prevalence of SRD in uveitis
patients imaged with OCT, correlation of visual acuity with
SRD, anatomic subtypes of uveitis identified, and associa-
tion of SRD with various subtypes of macular edema (focal
and diffuse) and retinal architectural abnormalities.
Design Retrospective, single-setting cross-sectional study
of all OCTs in a digital imaging base ordered on patients
from a tertiary referral uveitis clinic between July 2006 and
March 2008.
Results SRD were identified in 17 of 111 uveitis patients
(15 %) reviewed; bilateral SRD were found in 5 of 17
patients (29 %). Intermediate uveitis was the most common
disease association (47 %), but other conditions identified
included Vogt-Koyanagi-Harada syndrome, multifocal cho-
roiditis/panuveitis, and sarcoidosis. Retinal architectural
features identified in association with SRD included focal
macular edema (59 %), diffuse macular edema (50 %), any
intraretinal edema (77 %), both diffuse and focal macular
edema (32 %), and retinal pigment epithelial alteration
(27 %). Moderate or severe visual impairment, defined as
visual acuity 20/50 or poorer was seen in 71 % of patients
with SRD. Poorer visual acuity was correlated with in-
creased central subfield thickness in patients with SRD
(r200.41, p<0.001).
Conclusion SRD were present in 15 % of the uveitis patients
reviewed. Moderate to severe vision impairment was present
in the majority of eyes (71 %) with SRD. Diffuse macular
edema and focal cystoid macular edema were the OCT
features most commonly associated with SRD. Intermediate
and panuveitis were the most common anatomic sites of
inflammation. A variety of pathogenic mechanisms, both
inflammatory and non-inflammatory, may be involved in
SRD in uveitis patients; identification of the precise mecha-
nism is important for appropriate therapy.
Keywords Optical coherence tomography . OCT .
Uveitis . Serous retinal detachment .Macular edema .Vogt-
Koyanagi-Harada syndrome . Sarcoidosis . Acute posterior
multifocal placoid pigment epitheliopathy . Pars planitis .
Hypotony maculopathy . Choroidal neovascularization
Introduction
The term uveitis is used to describe a heterogenous group of
inflammatory diseases having in common intraocular
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inflammation. Uveitis is recognized as a leading cause of
blindness in the Western world that differentially affects
younger, working-age adults and children and causes vision
loss both due to direct effects and indirectly via secondary
anatomic complications such as cystoid macular edema.
Macular edema is present in up to 33 % of uveitis patients
and is responsible for visual impairment or blindness in
59 % of patients with panuveitis and 85 % of patients with
intermediate uveitis [1].
Our ability to resolve retinal architectural features has been
revolutionized by the advent of optical coherence tomography
(OCT), a highly sensitive method of obtaining cross-sectional
imaging of the retina to diagnose, follow, and characterize
macular edema in uveitis and other disease states. OCT is now
the most widely used modality for detecting macular disease
[2–5]. With this improved ability to characterize macular
ultrastructure, three subtypes of macular edema have been
identified [3, 5]. The first two, diffuse and cystoid macular
edema, are caused by intraretinal fluid accumulation in the
neurosensory retina. The third, serous retinal detachment
(SRD), is characterized by fluid accumulation in the potential
space between the macula and underlying retinal pigment
epithelium. Besides its presence in patients with macular
edema, neurosensory retinal detachment may also result from
other mechanisms independent of inflammation-associated
macular edema (e.g., choroidal neovascularization).
Prior studies have shown that SRDs are found in 15–
20 % of uveitis patients with macular edema [3, 5], but there
is conflicting literature as to the correlation between the
presence of SRD and decreased visual acuity. The prognos-
tic significance of SRD has not been established in the
literature and is difficult to assess given the heterogeneous
nature of secondary causes, including Vogt-Koyanagi-
Harada syndrome (VKH) [6, 7], toxoplasmosis [8], Behcet’s
disease [9, 10], and juvenile idiopathic arthritis.
Syndromes associated with uveitis, such as VKH, often
demonstrate retinal pigment epithelial (RPE) damage in addi-
tion to serous detachments. The destruction of the RPE layer
in association with serous detachments has been postulated to
be a result of inflammation and ischemic damage [2]. Our
study aimed to investigate the degree of visual impairment
present in eyes in our series with SRD and to examine the
spectrum of retinal morphological changes present with SRD
in association with a variety of disease processes.
Methods
We surveyed all OCTs and associated patient records from
patients from the Uveitis and Immunology service of the
Casey Eye Institute performed for diagnostic andmanagement
purposes between July 2006 and March 2008. Two separate
investigators (A.S-R and S.Y.) evaluated the OCTs for the
presence and type of macular edema, including diffuse and
cystoid macular edema and SRDs, and other OCT features. A
third investigator (B.C.K.) adjudicated any differences in the
presence of SRD and other abnormalities identified by OCT.
SRD were defined as an elevation of the neurosensory retina
with an optically clear space between the retina and the RPE
layer. Diffuse macular edema (DME) and cystoid macular
edema (CME) were defined according to previously described
patterns of macular edema in uveitis (i.e., DME, CME, SRD)
[3–5]. Fluorescein angiograms and fundus photography were
also reviewed in cases where SRDs were identified. Because
our study included patients with suspected macular disease,
some individuals with SRD in the absence of macular edema
were also captured in our imaging cohort. Of note, one patient
with central serous retinopathy was identified in our review.
Because this finding was considered unrelated to underlying
ocular inflammation, the patient was excluded from the statis-
tical analysis.
Our study protocol was Institutional Review Board-
approved, and all research conformed to the Association
for Research in Vision and Ophthalmology statement on
human research. Specific medical record data gathered for
each patient included age, gender, uveitis anatomic classifi-
cation based as defined by Standardization of Uveitis No-
menclature criteria [11], laterality, Snellen visual acuity,
associated systemic diagnoses, and the presence of other
local disease processes potentially contributing to the SRD
(e.g., concomitant choroidal neovascular membrane).
Optical coherence tomography protocol
OCT measurements were obtained using the Stratus OCT3
(software ver. 5.0), a time-domain OCT instrument (Carl
Zeiss, Meditec, Inc., Dublin, CA). Scanning was performed
using the fast macular thickness map protocol, consisting of
six evenly spaced 6-mm radial lines for quantitative meas-
urements; each line consisted of 128 A-scans, intersecting at
the fovea, for a total of 768 sampled points with a scanning
time of 1.9 s. Central 1-mm subfield thickness (Area A1)
was recorded using the manufacturer’s imaging software. In
instances when automated central macular thickness could
not be computed due to marked thickening, the caliper mode
on the Stratus OCT was used for a manual center point
thickness measurement. High-resolution vertical and hori-
zontal cross-hair patterns (9–3 o’clock and 6–12 o’clock)
were also obtained for assessment of evidence of overlying
macular edema (cystoid versus diffuse), retinal pigment
epithelium scar, and foveal atrophy.
Statistical analysis
Descriptive statistics were performed using Microsoft Excel
(Microsoft, Redmond, WA). Inferential statistics were
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performed using GraphPad Prism (La Jolla, CA). Patients
were classified according to the level of visual impairment
for descriptive purposes. Mild visual impairment was de-
fined as Snellen visual acuity of 20/25 to 20/40. Moderate
visual impairment was defined as visual acuity poorer than
or equal to 20/50 and better than 20/200. Severe visual
impairment was defined as visual acuity of 20/200 or poorer.
Snellen visual acuity was converted to the log of the mini-
mal angle of resolution (logMAR) visual acuity using the
formula logMAR VA0−log (decimal equivalent of Snellen
visual acuity). Linear regression and two-tailed Pearson
correlation analysis were performed to determine whether
a relationship existed between logMAR visual acuity and
central subfield thickness. An alpha of 0.05 was considered
statistically significant.
Results
OCTs from a total of 111 patients were reviewed, and of
these patients, 17 (15 %) patients demonstrated SRD by
OCT; five patients were bilaterally affected, resulting in a
total of 22 affected eyes. Twelve patients (71 %) were
female, and the mean age of patients was 39.8 years (range,
9–64 years). The mean visual logMAR visual acuity±stan-
dard deviation was 0.718±0.779 (Snellen visual acuity
equivalent 20/104). Eleven of 22 eyes (50%) showedmoderate
visual impairment, defined as VA≤20/50 and>20/200. Five
eyes (23 %) showed severe visual impairment, VA≤20/200.
The demographic characteristics and visual acuity of patients
are summarized in Table 1.
Identified secondary diagnoses are summarized in Table 1,
including VKH (two), sarcoidosis (one), acute posterior multi-
focal placoid pigment epitheliopathy (one), hypotony macul-
opathy (one), panuveitis-associated choroidal neovascular
membrane (one), and post-operative inflammation following
cataract removal (two).
Anatomic diagnoses included intermediate uveitis (eight
patients, 47 %), posterior uveitis (one patient, 6 %), and
panuveitis (eight patients, 47 %). Patients with anterior and
intermediate uveitis were classified as intermediate uveitis;
no patients with SRD with isolated anterior uveitis were
identified (Table 2).
The mean central subfield thickness (CST)±standard devi-
ation was 519 μm±341 (range, 210–1718 μm). Linear regres-
sion and two-tailed Pearson correlation analysis evaluating the
relationship of logMAR visual acuity and CST showed a
statistically significant positive correlation between poorer
logMAR visual acuity and increased CST (Fig. 1, r200.41,
p 00.0009).
Retinal architectural abnormalities identified on OCT,
which were associated with SRD, are summarized in Table 3.
These architectural abnormalities included diffuse macular
edema in 11 eyes (50 %), focal cystoid macular edema in 13
eyes (59 %), any intraretinal edema (diffuse or focal) in 17
of 22 eyes (77 %), both focal and diffuse macular edema in
seven eyes (32 %), and retinal pigment epithelium abnor-
malities in six eyes (27 %).
To illustrate the spectrum of disease processes identified
in this uveitis patient population, we have summarized here-
in four illustrative cases of patients identified in this series
with SRDs of varying etiologies, management strategies,
and prognostic implications.
Illustrative cases
Patient 7 is an 11-year-old male with pars planitis oculus
uterque (OU; both eyes), status post-pars plana vitrectomy/
cryotherapy OU and history of disease remission on meth-
otrexate who presented with increasing floaters and blurred
vision OU. His visual acuities were 20/40 oculus dexter
(OD; right eye) and 20/50 oculus sinister (OS; left eye). Slit
lamp examination was quiet OD and revealed 1+ anterior
Table 1 Characteristics of uveitis patients with SRD
Total no. of patients 17
Male (%) 5 (29)
Female 12 (71)
Laterality
Unilateral (%) 12 (71)
Bilateral 5 (29)
Mean age, years (range) 39.8 (9–64)
Visual acuity, logMAR±SD (Snellen) 0.718±0.779 (20/104)
No. of eyes at degree of visual
impairment (%)
22 (100)
Mild 20/25-20/40 6 (27)
Moderate 20/50–20/160 11 (50)
Severe 20/200 or worse 5 (23)
Anatomic location of uveitis




Associated syndrome No. of patients (%)
Idiopathic 9 (41)
Vogt-Koyanagi-Harada (VKH) 2 (12)
Postoperative 2 (12)
Sarcoidosis 1 (6)
Acute posterior multifocal placoid pigment
epitheliopathy (APMPPE)
1 (6)




logMAR log minimal angle of resolution, VA visual acuity, SD standard
deviation
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chamber inflammation OS and 1+ vitreous cell OS. Dilated
funduscopic examination showed peripheral cryotherapy
scars OU and cystoid macular edema OS. OCT demonstrat-
ed a foveal SRD with overlying cystoid macular edema with
overlying focal cystoid macular edema (Fig. 2).
Methotrexate 15 mg/week and slow prednisone taper
were prescribed. Four weeks thereafter, the visual acuity
improved to 20/40 OS with an improvement in inflamma-
tion to trace anterior chamber cell and trace vitreous cell OS.
The focal cystoid macular edema and SRD had completely
resolved (Fig. 2). At 21 months follow-up, the visual acuity
Table 2 Systemic and ophthalmic diagnoses and OCT features of uveitis patients with SRD





Visual acuity DME CME RPE
change
CST
1 45/F OS Anterior and intermediate Idiopathic 20/30 + + + 546
2 49/F OD Anterior and intermediate Idiopathic 20/50 + 554
OS 20/50 + 455
3 37/M OD Anterior and intermediate Idiopathic 20/60 + + 372
4 46/F OD Anterior and intermediate Idiopathic 20/25 194
5 59/F OS Anterior and intermediate Chronic,
postoperative uveitis
20/200 + 715
6 64/F OD Intermediate Idiopathic 20/70 + + 645
OS 20/70 + + 463
7 11/M OS Intermediate Pars planitis 20/50 + 492
8 29/M OS Intermediate Chronic,
postoperative uveitis
20/400 + + 279
9 12/F OD Panuveitis Idiopathic 20/50 + + 533
10 42/F OS Panuveitis Idiopathic 20/30 + 210
11 9/F OD Panuveitis Idiopathic 20/40 + 459
OS 20/40 + 532
12 53/M OS Panuveitis Idiopathic CNVM 20/50 + + 322
13 45/F OS Panuveitis MFC/PU Hypotony
maculopathy
CF + + 1718
14 57/F OD Panuveitis Sarcoidosis 20/50 + + 311
OS 20/100 + 235
15 30/M OD Panuveitis VKH 20/30 285
16 39/F OD Panuveitis VKH CF + + 1168
OS CF + 443
17 49/F OD Posterior APMPPE 20/50 307
VKH Vogt-Koyanagi Harada disease, CF counting fingers, CSR central serous retinopathy, CNVM choroidal neovascular membrane, MFC/PU
Multifocal choroiditis/panuveitis syndrome, DME diffuse macular edema, CME cystoid macular edema, RPE retinal pigment epithelium, PED
pigment epithelial detachment
Fig. 1 LogMAR visual acuity versus central subfield thickness in
patients with SRD. Linear regression curve shows a positive slope
and two-tailed Pearson correlation analysis shows r200.41 (p00.0009)
Table 3 Retinal architectural findings associated with SRD
Retinal architectural finding No. of eyes (%)
Total 22 (100)
Any intraretinal edema (diffuse or cystoid) 17 (77)
Diffuse macular edema 11 (50)
Focal cystoid macular edema 13 (59)
Both diffuse and focal macular edema 7 (32)
Retinal pigment epithelium change 6 (27)
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was stable at 20/30 OS on methotrexate therapy, and no
evidence of recurrent inflammation was seen.
Patient 17 is a 39-year-old Latin American woman who
presented with blurred vision, headaches, tinnitus, and pan-
uveitis with multiple exudative retinal detachments OU of
3 weeks duration. She had been treated unsuccessfully with
topical prednisolone acetate 1 % and atropine 1 % BID.
Visual acuity on presentation was counting fingers OU. Slit
lamp examination showed 3+ anterior chamber cell OU and
2+ vitreous cells OU. Detailed funduscopic features were
difficult to appreciate secondary to 2+ vitreous haze OU.
There was severe optic disc edema OU and multiple neuro-
sensory retinal detachments OU, which were demonstrated by
OCT (Fig. 3). Acute Vogt-Koyanagi-Harada’s disease was
diagnosed, and methylprednisolone 1 mg/kg×three doses
was administered intravenously followed by prednisone
1 mg/kg/day orally. Prednisone was slowly tapered off, and
mycophenolate mofetil 1 g twice daily was started with main-
tenance of clinical disease remission. At 20months follow-up,
the patient’s visual acuity was 20/30 OD and 20/40 OS.
Funduscopic examination showed a typical “sunset-glow”
fundus of VKH from choroidal depigmentation and resolution
of the SRDs.
Discussion
In this study, we identified SRDs in 15 % of all patients with
uveitis who underwent time-domain OCT imaging due to
suspected macular pathology. Intermediate and panuveitis
were the most common anatomic sites of inflammation,
which is consistent with prior research evaluating uveitic
macular edema [1]. Moderate or severe visual impairment
was identified in 71 % of patients in this series. We also
found that increased CST was correlated with poorer log-
MAR visual acuity in patients with SRD. Whether de-
creased vision was a direct result of the SRD is difficult to
ascertain due to high prevalence of concurrent intraretinal
macular edema, which may also cause reduced visual acuity.
Other factors including photoreceptor integrity, presence or
absence of foveal atrophy, and chronicity of macular edema
likely contributed to visual impairment, but these factors
were not specifically addressed in the context of this study.
Diffuse macular edema and focal cystoid macular edema
were the OCT features most commonly associated with
SRD. The focal subtype of macular edema was most com-
monly identified while the diffuse subtype was also seen in a
large proportion of patients. Patients with intermediate
Fig. 2 OCT and macular
thickness map of a SRD in an 11-
year-old patient with pars planitis.
Focal cysts overlying a SRD are
seen a with central macular
thickening and a central subfield
thickness of 492 um (b). Follow-
ing an oral prednisone taper and
methotrexate immunosuppres-
sion, the SRD and focal cystoid
macular edema have resolved (c)
with an improvement in visual
acuity, decrease in visual symp-
toms, and restoration of normal
macular thickness on the macular
thickness with a central subfield
thickness of 184 um (d)
Fig. 3 Fundus photograph and
OCT of a patient with acute
VKH disease. Fundus
photograph show vitreous haze,
optic disc edema, and multiple
exudative detachment involving
the posterior pole (a). OCT
reveals dome-shaped SRD with
intraretinal, focal cystoid edema
OD (b)
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uveitis and cystoid macular edema comprised the majority
of patients with OCT evidence of SRD and is consistent
with prior series of patients with macular edema in tertiary
referral settings [3, 12].
A variety of pathogenic mechanisms appear to be involved
in the development of SRD in the uveitis population. Macular
edema, the retinal architectural feature and clinically identifi-
able feature typically prompting OCTevaluation, is caused by
inflammatory disruption of the normal permeability of the
blood–retinal barrier.
Uveitis therapy with corticosteroids or other immunosup-
pressive medications leads to reduction in inflammation,
restoration of vascular permeability, and subsequent resolu-
tion of the SRD and macular edema. However, because of the
variety and diversity of etiologies associated with uveitis,
other mechanisms are likely involved as well.
In VKH, breakdown of the blood–retinal barrier from iris
and ciliary body inflammation is likely compounded by
choroidal inflammation, overlying RPE injury and poor
RPE pump function leading to the massive exudative
detachments found in this disease process. In patients with
multifocal choroiditis and punctate inner choroidopathy,
subretinal fluid may accumulate following the formation of
a choroidal neovascular complex, a consequence of both
inflammatory and angiogenic pathways. Increased levels
of vascular endothelial growth factor (VEGF) have been
identified in the aqueous humor of uveitis patients [13], and
recently, anti-VEGF therapy with and without concomitant
immunosuppressive medication has been successfully used
for the treatment of uveitis-associated choroidal neovascular
membrane (CNVM) [14, 15].
Within this series of patients, the specific therapy re-
quired to treat the process and associated SRD varied
according to the disease process. Specifically, corticosteroid
treatment was indicated for treatment of SRD secondary to
inflammation as in intermediate uveitis and VKH; however,
in patients with SRD due to CNVM, anti-VEGF and anti-
inflammatory medications were required. Central serous
retinopathy, although not specifically addressed in the con-
text of this study, is another important etiology to consider,
as corticosteroid use is nearly ubiquitous in the uveitis
patient population and requires corticosteroid withdrawal
to expedite its resolution.
The limitations of this study include the retrospective,
cross-sectional nature of the study. Any study from tertiary
referrals centers is prone to ascertainment bias, potentially
skewing the proportion of uveitis patients with SRD. Con-
versely, some patients with advanced uveitis and severe
vitritis and retinitis were excluded by the nature of the
severity of their disease, which may cause significant media
opacity precluding OCT imaging. Only a subset of patients
with uveitis was characterized by OCT, and this subset
mostly included patients with suspected macular edema.
Lastly, our study exclusively used time-domain OCT, which
utilizes 400 axial A-scans per second to achieve an axial
resolution of 10 μm, whereas newer spectral domain OCT
technology utilizes 20,000 A-scans per second to achieve a
resolution approaching 5 μm. Moreover, because the retinal
segmentation algorithms of spectral domain (SD)-OCT may
result in greater macular thicknesses when compared with
the algorithms of the time domain-OCT protocol used in this
investigation, the CST measured in this study may be under-
estimated in patients with SRD.
Despite these limitations, we were able to identify spe-
cific uveitis syndromes in which SRD was a key clinical
feature and described OCT characteristics valuable for plan-
ning future longitudinal studies employing SD-OCT strate-
gies in the measurement of structural outcomes. Future
prospective studies are needed and could provide more
objective data by comparing the presence of SRDs in uveitis
patients without macular edema to those with macular ede-
ma and might better define the visual prognostic signifi-
cance of different subtypes of uveitic macular edema and
their response to therapy.
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